A new analysis in the CGT manufacturing space highlights ongoing vulnerabilities around viral contamination, pointing to raw materials as the biggest source of risk. The report notes that conventional virus inactivation and removal approaches can damage cells or compromise viral vectors used in gene therapies, making screening strategies the dominant safety approach. The article also cites regulatory expectations and emphasizes the importance of robust testing programs for both raw materials and finished products. It flags NGS-based methods as a potential route for improved detection of adventitious viruses. For cell and gene therapy developers, the update reinforces that process controls and supplier qualification remain the practical backbone of viral safety as manufacturing scales.